The Correlation Between MDR1 Gene Polymorphism and Clopidogrel Resistance in People of the Hui and Han Nationalities

Jing Zhang, MD1, Zhi-Feng Dong, MD2, Cheng-Xue Bian, MD3, Xuan Zhang, MD4, Xiang-Bin Xin, MD5, and Fang Chen, MD2

Abstract
To investigate the differences in the correlation between multidrug resistance protein 1 (MDR1) (ABCB1) gene polymorphism and clopidogrel resistance in patients of the Hui and Han nationalities with percutaneous coronary intervention (PCI). A total of 377 subjects (154 people of Hui nationality, 223 people of Han nationality) with PCI were enrolled in the study. Each patient’s platelet aggregation rate was induced by adenosine diphosphate and measured using light turbidimetry. Based on the results, the patients were divided into two groups: a clopidogrel resistance (CR) group and a non-clopidogrel resistance (NCR) group. Restrictive fragment-length polymorphism polymerase chain reaction technology was then used to determine the genotype and alleles at two loci (C3435 T[rs1045642] and C1236 T[rs1128503]), calculate the frequencies of the genotype and alleles at these two loci (C3435 T[C3435 T] and C1236 T[C1236 T]), and conduct correlation analysis. The incidence rate of clopidogrel resistance was 23.4%, and the frequencies of the TT genotype and T allele at C3435 T for patients of both nationalities were significantly higher in the CR group than in the NCR group (P < 0.05). There were no significant differences between the two groups in genotype or allele frequency at C1236 T. There was a significant difference in the distribution of C1236 T polymorphism between the two nationalities (P < 0.05), but there was no significant difference between the two nationalities in C3435 T polymorphism. Patients with a T allele at MDR1 C3435 T are more likely to show clopidogrel resistance, and no significant differences were identified in C3435 T gene polymorphism between the two nationalities.

Keywords
coronary heart disease, MDR1 gene, clopidogrel resistance, gene polymorphism, ethnic differences

Date received: 12 October 2021; revised: 17 December 2021; accepted: 23 December 2021.

Introduction
Coronary heart disease (CHD) is a cardiovascular disease that poses a serious threat to human health. Percutaneous coronary intervention (PCI) has become an important approach for the treatment of this disease. If there are no contraindications or high bleeding risks after PCI surgery, the administration of aspirin combined with clopidogrel, which acts as a P2Y12 receptor inhibitor and an antiplatelet treatment (loading amount 300-600 mg, maintenance dose 75 mg daily), is recommended for 12 months. Recently, however, both domestic and international reports have identified significant individual variations in clopidogrel anti-platelet therapy: even after regular oral administration of the standard dose of clopidogrel, some patients experience a recurrence of myocardial infarction and stent thrombosis.

This indicates a form of clopidogrel resistance that increases the possibility of clinical cardiovascular adverse events in patients after PCI surgery. After oral administration, clopidogrel needs to

1 Yantai Yuhuangding Hospital Affiliated to Qingdao Medical University, Yantai, China
2 The First People’s Hospital of Yinchuan, Yinchuan, China
3 Jingbian People’s Hospital, Yulin, China
4 Xi’an International Medical Centre, Xi’an, China
5 Zhangye People’s Hospital Affiliated to Hexi University, Zhangye, China

Corresponding Author:
Fang Chen, Department of Cardiovascular internal Medicine, The First People’s Hospital of Yinchuan, No.40 of Liiqun West Street, Xingqing District, Yinchuan 750001, China.
Email: chenfang_qq33@163.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
be converted into active products through a metabolic reaction via the liver CYP450 enzyme, and many other enzymes are also involved in this process. Therefore, it is currently believed that the poor response to cilupidogrel is related to the polymorphism of genes in its metabolic pathway, including cytochrome P450 2C19 (CYP2C19) and multidrug resistance protein 1 (MDR1).

To date, research on CYP2C19 has offered the clearest results, while the results of studies on the MDR1 gene have been inconsistent. The MDR1 gene can encode the transporter P-glycoprotein of the small intestinal epithelium to regulate the absorption of cilupidogrel. It has been reported that, among many single-nucleotide polymorphisms of MDR1, C1236 T and C3435 T may be related to the defects in P-glycoprotein.

Although there are many reports regarding the wide variation of MDR1 gene polymorphism between populations and races in different regions, there have been few studies involving the Hui population. The Hui people are, genetically, a relatively isolated nationality: the communities of this population live close together in the northwest of China, particularly in the Ningxia Hui Autonomous Region, and most people of Hui nationality are prohibited from marrying people from other ethnic groups. For these reasons, people of Hui nationality were selected as one of the populations for the present study.

This study enrolled patients of Hui or Han nationality with CHD who underwent PCI and received oral cilupidogrel after the procedure. Their genotypes and alleles related to cilupidogrel resistance were screened, the association between MDR1 gene polymorphism and cilupidogrel resistance was evaluated, and the differences between the results for the two nationalities were further analyzed. It is hoped that the study will have significant theoretical value in the individualized treatment of patients using cilupidogrel.

**Subjects and Methods**

**Subjects**

A total of 377 patients who received PCI in the cardiology department at the General Hospital of Ningxia Medical University or the First People’s Hospital of Yinchuan between May 2015 and January 2017 were enrolled, comprising 154 people of Hui nationality and 223 people of Han nationality.

The inclusion criteria for patients were as follows: (1) no interracial marriage within three generations and no consanguinity with other enrolled patients; (2) aged 18 to 80 years; (3) had received PCI treatment, with one or two stents implanted; (4) before the procedure, had received oral administration of enteric-coated aspirin 100 mg regularly for at least 1 week and cilupidogrel bisulfate tablets (Plavix) 300 mg once daily, followed by an oral maintenance dose of 75 mg; and (5) had received oral dose of atorvastatin calcium tablets (40 mg daily) and undergone subcutaneous injection of low-molecular-weight heparin calcium according to body weight for anticoagulant therapy.

The exclusion criteria were as follows: (1) contraindications for anti-platelet therapy; (2) patient had previously received cilupidogrel treatment or coronary artery bypass grafting/PCI surgery; (3) severe liver and kidney problems, digestive system diseases, acute and chronic blood system diseases, tumors or other end-stage diseases, or severe heart insufficiency; (4) patient had recently received platelet glycoprotein IIb/IIIa inhibitors; and (5) patient had simultaneously received orally administered rifampicin, erythromycin, and intervention with a proton pump inhibitor.

All participants in the study received professional training in compliance with the principle of voluntary participation. This study was conducted with the approval of the Ethics Committee of Yinchuan First People’s Hospital. Written informed consent was obtained from all participants.

**Table 1. Comparison of General Data Between CR Group and NCR Group in Hui and Han Nationality.**

| Items                  | Hui             | Han             |
|------------------------|-----------------|-----------------|
|                        | CR (n = 40)     | NCR (n = 63)    | CR (n = 160)   | NCR |
| Age                    | 59.13 ± 8.94    | 60.23 ± 8.71    | 61.63 ± 8.7    | 59.06 ± 9.33 |
| Male/n(%)              | 26 (65.0)       | 92 (80.7)       | 45 (71.4)      | 112 (70.0)   |
| Hypertension/n(%)      | 26 (65.0)       | 90 (78.9)       | 37 (58.7)      | 80 (50.0)    |
| Diabetes/n(%)          | 16 (32.7)       | 50 (32.3)       | 49 (68.1)      | 63 (38.7)*   |
| Smoking history/n(%)   | 14 (35.0)       | 43 (37.7)       | 27 (42.8)      | 74 (46.2)    |
| BMI(Kg/m2)             | 27.22 ± 30.01   | 25.14 ± 3.21    | 26.79 ± 5.07   | 24.35 ± 3.11*|
| TG(mmol/L)             | 2.31 ± 1.79     | 1.81 ± 1.00     | 2.11 ± 1.09    | 1.54 ± 0.78*|
| CHOL(mg/dl)            | 3.73 ± 1.14     | 3.78 ± 2.45     | 3.97 ± 1.04    | 3.94 ± 1.15  |
| FG(mmol/L)             | 7.45 ± 2.89     | 6.55 ± 2.89     | 7.37 ± 2.74    | 6.65 ± 2.81  |
| UA(mmol/L)             | 321.07 ± 84.23  | 327.05 ± 90.06  | 291.81 ± 80.72| 301.04 ± 84.45|

Note: *P < 0.05 , the difference was statistically significant.

Abbreviations: BMI, body mass index; TG, triglyceride; CHOL, cholesterol; FG, Fasting blood glucose; UA, uric acid.
A Siemens ADVIA 2400 automatic biochemical analyzer (Siemens, Germany) was used to measure all biochemical indicators. The specific indicators used are shown in Table 1.

**Platelet Function Assay**

During the morning after the PCI procedure, 2 mL of fasting venous blood was collected from the patient in an ethylenediaminetetraacetic acid (EDTA) anticoagulation tube, and a further 2 mL was collected in a sodium citrate anticoagulation tube. The sample in the EDTA anticoagulation tube was centrifuged at 3500 r/min, and the middle and lower blood cells were extracted and stored in a refrigerator at −80 °C. The sodium citrate anticoagulation tube was sent to the First People’s Hospital of Yinchuan City for platelet aggregation determination within 2 h. The platelet aggregation rate was measured using an LBY-NJ4 platelet aggregometer (Beijing Precil, China). Based on the results, the patients were divided into two groups, a clopidogrel resistance (CR) group and a non-clopidogrel resistance (NCR) group, with a platelet aggregation rate of ≥50% defined as clopidogrel resistance.7

**Test Methods**

Extraction of peripheral blood DNA: The stored blood samples were removed for extraction of the peripheral blood DNA using a Tiangen blood genomic DNA extraction kit (centrifugal column type; Tiangen, Beijing, China). The purity and concentration of the DNA samples were measured using a Nanodrop 2000 spectrophotometer (NanoDrop Technologies, LLC, Wilmington, Delaware, USA).

Polymerase chain reaction (PCR) amplification: Primers were synthesized by Sangon Biotech (Shanghai, China) following literature review. The C3435 T primer sequence was as follows: P1 = 5′-TCTCTGTTTACTTTATCCAGC-3′; P2 = 5′-ACATTTAGGCAGTGACTCGATGAAGGC-3′. The C1236 T primer sequence was as follows: P1 = 5′-TGCTGGTCCTGAAGTTGATCTGTGAA-3′; P2 = 5′-ACATTAGGCAGTGACTCGATGAAGGC-3′. The C1236 T primer sequence was as follows: P1 = 5′-TGCTGGTCCTGAAGTTGATCTGTGAA-3′; P2 = 5′-TCTCACCATCCCCTCTGT-3′. The PCR reaction conditions were as follows: pre-denatured at 94 °C for 5 min, denatured at 94 °C for 30 s, annealed at 60 °C for 30 s, and extended at 72 °C for 1 min. The whole process was cycled 30 times and extended at 72 °C for 10 min.

Enzyme digestion: In accordance with previous research,8–10 the restriction enzyme obtained at the C3435 T locus was DpnII (New England Biolabs [NEB], USA), and the restriction enzyme at the C1236 T locus was Eco0109I (NEB, USA). Binary logistic regression analysis was used to analyze the correlations between genotype, blood glucose, BMI, age, gender, blood pressure, blood lipid levels, uric acid, smoking status, and clopidogrel resistance. A P value of <0.05 was considered statistically significant.

**Results**

**Electrophoresis**

It is currently thought that the mutation frequency of genes might vary for different populations: the same gene mutation may occur at varying intensities due to differences in environment. After enzyme digestion at the C1236 T locus of the MDR1 gene, there was no enzyme digestion site for the T allele, and one enzyme digestion site was presented after mutation of T into C. The electrophoresis results were verified by sequencing. CC was cut into two fragments (379 and 123 bp, respectively), and CT was cut into three fragments (502, 379, and 123 bp, respectively). TT could not be cut, so there was just one fragment (502 bp).

After enzyme digestion at the C3435 T site of the MDR1 gene, CT was cut into three fragments (248, 190, and 58 bp, respectively), and CC was cut into two fragments (190 and 58 bp, respectively). TT could not be recognized and cleaved by endonuclease, so there was only one fragment (248 bp). Although it seems that the C3435 T might have one more constitutive cleavage site for DpnII, after DNA sequencing, we found that the number and the length of the obtained RFLP fragments, especially the genotypes, would not be affected.

**Genotype and Allele Frequency Distribution**

There was no significant difference between the genotype and allele frequencies at the C3435 T locus (P > 0.05) for the Han and Hui CR groups or for the Han and Hui NCR groups, but there were significant differences in the frequencies at the C1236 T locus (P < 0.05).

There were significant differences between the genotype and allele frequencies of the polymorphism distribution at the C3435 T locus between the CR group and NCR group for both nationalities, with significantly higher frequency distributions of the TT genotype and T allele in the CR group than in the NCR group (P < 0.05). There were no significant differences in the genotype and allele frequencies at the C1236 T locus between the CR and NCR groups (P > 0.05; Table 2).

**Statistical Processing**

All analyses were conducted using SPSS 19.0 software. The measurement data were expressed as mean ± standard deviation, and the counting data were expressed as frequency values. The measurement data of the two groups were compared using t-testing, and the counting data were compared using χ² testing. The representativeness of samples was assessed using the Hardy–Weinberg equilibrium. Binary logistic regression analysis was used to analyze the correlations between genotype, blood glucose, BMI, age, gender, blood pressure, blood lipid levels, uric acid, smoking status, and clopidogrel resistance. A P value of <0.05 was considered statistically significant.
Clopidogrel is a widely used drug for CHD treatment and post-PCI antiplatelet therapy, but clopidogrel resistance can limit its clinical efficacy. However, different testing methods for clopidogrel resistance use different standards and definitions. Müller defined clopidogrel resistance based on adenosine diphosphate-induced platelet aggregation decreasing by 10% or less compared with the baseline value in the 4 h after administration of 600 mg of clopidogrel. Barragan, however, proposed defining clopidogrel resistance as a platelet aggregation rate greater than 50% after administration of 600 mg of clopidogrel. Different testing methods have also reported varying incidence rates of clopidogrel resistance, ranging between 4% and 31%. The present study used the incidence rate of clopidogrel resistance obtained by Barragan (23.4%).

At present, the mechanism of clopidogrel resistance is unclear. While the interaction of patient compliance, dosage of medication, and drugs used may contribute to clopidogrel resistance, genetic factors may also affect the metabolism and absorption of active clopidogrel products. P-glycoprotein is expressed through the MDR1 gene, which is involved in the regulation of the intestinal absorption of active clopidogrel products, so it may be related to the occurrence of clopidogrel resistance.

Gutiérrez-Rubio’s study showed that the mutation rate of the MDR1 gene is relatively high in people of Han nationality and that the distribution of the MDR1 gene may vary between different groups. The frequency of a T mutation gene at the C3435 T locus was found to be higher in an Asian population than in an African population (Ghana 17%, Kenya 17%, Sudan 27%, Japan 39%, Caucasus 42%, India 62%), with an almost-zero frequency distribution of TT genotypes reported in the African population (Ghanaians 0%, Kenyans 4%, Sudanese 6%), which is significantly lower than for other groups. In the present study, the TT genotype frequency was 18.3% and the T allele frequency was 38.7%; these figures are similar to the T-mutation-gene frequency at the C3435 T locus in the Japanese population. In our research, to identify any differences between people of Hui and Han nationalities, we analyzed findings for the subjects of these two nationalities separately. The results showed no significant differences between the two nationalities (P > 0.05). To date, there have been few studies on the C1236 T locus, although significant differences exist among different ethnic groups. The analysis and comparison of the C1236 T locus CC, CT, and TT genotypes and C and T allele frequencies of the two groups in the present study indicate significant differences between the nationalities (P < 0.05).

---

**Discussion**

**Hardy–Weinberg Equilibrium Test**

The Hardy–Weinberg balance test was performed on the genotypes of the Hui and Han subjects. All the results had P values of >0.05, indicating that the subjects within each nationality group came from the same large population with good representativeness.

**Logistic Regression Analysis of the Correlation Between MDR1 Gene Polymorphism and Clopidogrel Resistance**

We introduced the following variables into the model for binary logistic regression analysis: clopidogrel resistance as the dependent variable; and a medical history of diabetes, fasting glucose, total cholesterol, body mass index (BMI), the C3435 T allele (introduced as a dummy variable compared with CC type), and C1236 T (introduced as a dummy variable compared with CC type) as the observed variables. The results indicated that 3435TT (odds ratio [OR] value = 2.307, OR 95% confidence interval [CI] = 1.010–2.879, P = 0.005) and diabetes history (OR value = 1.714, OR 95%CI = 1.013–2.907, P = 0.038) were independent risk factors for clopidogrel resistance, and no obvious correlations were found between any other factors and clopidogrel resistance.
Differing results have been reported regarding the correlation between the genetic polymorphism of the \textit{MDR1} C3435 T locus and clopidogrel resistance. Multiple large-scale clinical trials have shown that T mutation at the C3435 T site can reduce the rate of clopidogrel metabolism, reduce inhibition of platelet activity, and increase risk of thrombosis. In addition, it has been reported that wild-type C-gene carriers present the greatest risk of thrombosis. In the present study, regardless of nationality, TT genotype and T allele frequencies were significantly higher in the CR group than in the NCR group (P < 0.05), indicating that T-site mutation may cause clopidogrel resistance. However, the results of a previous study on the association between the C1236 T site and clopidogrel resistance differ from these findings. Some researchers have found that the CC wild type has a lower platelet inhibition rate than the CT + TT mutant type, but other domestic and international studies have identified no significant correlation between C1236 T and antiplatelet-drug resistance. In the present study, no statistical difference was identified between the genotype and allele frequencies for the two nationalities, indicating that C1236 T polymorphism is related to clopidogrel resistance. However, the small sample size of the study was a limitation for the research process; therefore, further research with larger samples is required to confirm the correlation between C1236T-locus gene mutation and clopidogrel resistance.

Previous studies have shown that the pharmacodynamic effects of antiplatelet drugs are lower in patients with diabetes than in those without diabetes (P < 0.05), and patients with myocardial infarction with blood glucose levels >8.5 mmol/L have generally shown a decreased reaction to clopidogrel. It has therefore been suggested that blood glucose may have some influence on the occurrence of clopidogrel resistance. In the baseline data of the present study, among the patients of Han nationality, there was a significantly higher proportion of patients with diabetes in the CR group than in the NCR group; this is consistent with the findings of these previous studies. However, a similar discrepancy was not found among the patients of Hui nationality in our sample.

Many clinical studies have shown that obesity and hyperlipidemia are closely related to cardiovascular diseases such as hypertension and atherosclerosis. Dogan et al. found a significantly increased incidence of clopidogrel resistance in patients with BMI > 30. Comparison of the baseline data in the present study identified significant differences between the two Han groups in cholesterol and BMI levels, which is consistent with the results of Dogan et al.’s study; however, significant differences were not found between the two Hui groups. The discrepancies in these results could be related to the different dietary habits of people of the Hui and Han nationalities; further studies with larger samples may report different results.

To further explore the correlation between \textit{MDR1} genetic polymorphism and clopidogrel resistance in the present study, a multifactor logistic regression equation was applied. Clopidogrel resistance as the dependent variable, and the C3435 T and C1236 T genotypes (introduced as dummy variables compared with CC type) as independent variables, were introduced into the model for analysis. The results identified both a TT genotype at the C3435 T locus and diabetes as independent risk factors for clopidogrel resistance; the latter is consistent with the findings reported by Hochholzer.

The present study’s findings indicated a correlation between polymorphism of the C3435 T locus and clopidogrel resistance. The T allele may be a susceptibility gene for clopidogrel resistance, but the polymorphism of the C3435 T locus differed between patients of the Hui and Han nationalities. The occurrence of polymorphism of the C1236 T locus also differed between patients of the Hui and Han nationalities, but there was no obvious correlation of this factor with the occurrence of clopidogrel resistance. From a comprehensive analysis, considering that there may be linkage disequilibrium reactions at different loci in the same gene, we suggest that single-locus polymorphism may not change the coding protein performance.

The present study had some limitations. As the subjects were limited to residents of the Ningxia Hui Autonomous Region, the sample size was small. The dosage of clopidogrel was low, and the platelet aggregation rate level was not measured before medication was administered. In addition, there were multiple factors related to clopidogrel resistance in the baseline data, which may have affected the results. For further study and confirmation, future research should use larger samples and control for all influencing factors. The \textit{MDR1} gene could also be associated with other genes related to clopidogrel metabolism for multigene correlation; this would offer increased opportunities to study the correlation between clopidogrel resistance and gene polymorphism, comprehensively clarify the relationship between clopidogrel resistance and \textit{MDR1} gene polymorphism, and develop a basis for early intervention and prediction of clopidogrel resistance.

\section*{Conclusion}

Patients with a T allele at \textit{MDR1} C3435 T were found to be more likely to show clopidogrel resistance, and no significant differences in C3435 T gene polymorphism were identified between the Hui and Han nationality groups. Differences were identified in C1236 T gene polymorphism distribution between the two nationalities, but this factor showed no significant correlation with clopidogrel resistance. Finally, no significant difference was found between the two nationalities in terms of the correlation between \textit{MDR1} gene polymorphism and clopidogrel resistance.

\section*{Ethics Approval and Consent to Participation}

I confirm that I have read the Editorial Policy pages. This study was conducted with approval of the Ethics Committee of Yinchuan First People’s Hospital. This study was conducted in accordance with the declaration of Helsinki. Written informed consent has been obtained from all participants.

\section*{Consent for Publication}

All participants have signed documents with informed consent.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Ningxia Province Science and Technology Support Project (grant number 2012ZYS212).

ORCID iD
Fang Chen https://orcid.org/0000-0001-6628-6644

References
1. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179-1189.

2. Guo YY, Wang LY, Zhang Y, ZHnag WJ, Liao P. [Relationship between CYP2C19 gene polymorphism with clinical adverse events and clopidogrel resistance in patients with coronary heart disease]. Jian Yan Yi Xue Yu Lin Chuang. 2021;18(8):1054-1058. (In Chinese)

3. Yang J, Yang ZY. [Research status of CYP2C19 gene polymorphism and clopidogrel resistance]. Lin Chuang Xin Xue Guan Bing Za Zhi. 2012;28(3):163-165. (In Chinese)

4. Dong DH, Song J, Zheng HY, et al. [Effects of CYP2C19 681 G > A and 636 G > A gene polymorphisms on platelet activity and clinical prognosis in patients with coronary heart disease treated with clopidogrel after PCI]. Zhong Guo Dong Mai Ying Hua Za Zhi. 2013;21(7):639-643. (In Chinese)

5. Tang K, Ngoi SM, Gwee PC, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic asian populations. Pharmacogenet. 2002;12(6):437-450.

6. Li D, Zhang GL, Lou YQ, et al. Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han. Ugger an Kazakh ethnic groups. J Clin Pharm Ther. 2007;32(1):89-95.

7. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance tothienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator stimulated phosphoprotein ephosphorylation. Catheter Cardiovasc Interv. 2003;59(3):295-302.

8. Chen WW. [thOct1. ABC. (B1), gene expression and ABCB1 single nucleotide polymorphism are correlated with the efficacy of Imatinib mesylate treatment in chonic myelocytic leukemia][D].2012.(In Chinese). https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CMFD&dbname=CMFD201301&filename =1013123289.nh&uniplatform=NZKPT&v=YxH5EYjyjyVvct l1vHBZh4WaZlziGLchwXMJ8mVGO4APoNqS2-LswFP4Y1 S5mMuSM

9. Li XF, [The association between polymorphisms of MDR1 and chemotherapy sensitivity in ovarian cancer patients][D].2010.(In Chinese)

10. Zheng QC, Feng Y, Xiao L, et al. MDR1 Gene single nucleotide polymorphism and haplotype in chongqing Han populations. J Fourth MilMed Univ. 2009;30(22):2631-2634.

11. Müller I, Besta F, Schulze C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003;89(5):783-787.

12. Li JF, Yan L, Wang XF, et al. [Effects of high fat diet and ABCB1 gene polymorphism on pharmacokinetics of nifedipine in healthy subjects]. Zhong Guo Yao Li Xue Tong Bao. 2014;30(4):566-569. (In Chinese)

13. Gutierrez-Rubio SA, Quintero-Ramos A, Durán-Cárdenas A, et al. C/T and 3435 C/T polymorphisms of the ABCB1 gene in Mexican breast cancer patients. Genet Mol Res. 2015;14(1):1250-1259.

14. YH L, YH W. MDR1 Gene polymorphisms and clinical relevance. Acta Genet Sin. 2006;33(2):93-104.

15. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1(pglycoprotein):recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75(1):13-33.

16. Mega J L, Close S L, Wiviott S D, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376(9749):1312-1319.

17. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375.

18. Su J, Xu J, Li X, et al. ABCB1 C3435 T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PloS One. 2012;7(10):e46366.

19. Su J. [Correlation between ABCB1 gene polymorphism and clopidogrel resistance][D].2014. (In Chinese)

20. Tang X F, Wang J, Zhang J H, et al. Effect of the CYP2C19 2 and 3 genotypes. ABC. (B1):c3435 T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol. 2013;69(5):1103-1111.

21. Kuliczkowski W, Gasior M, Pres D, et al. Effect of glycemic control on response to antiplatelet therapy in patients with diabetes Mellitus and ST-segment elevation myocardial infarction. Am J Cardiol. 2012;110(3):331-336.

22. Doğan A, Kahraman S, Usta E, Özdemir E, Görmüş U, Çiftçi C. Effect of obesity and serum leptin level on clopidogrel resistance. Turk Kardiyol Dern Ars. 2016;44(7):548-553.

23. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol. 2010;55(22):2427-2434.